Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care.
Pharmacogenomics is a term recently coined to embody the concept of individualized and rational drug selection based on the genotype of a particular patient. Customization of drug therapy offers the potential for optimal safety and efficacy in an individual patient. Such a process contrasts current prescribing practices, which use medications shown to be safe and effective in patient populations or based on anecdotal experiences. Within patient populations, medications vary in their efficacy among individual patients. More importantly, a medication that is safe and effective in one patient may be ineffective or even harmful in another. Underlying many of these phenotypic differences are genotypic variants (polymorphisms) of key enzymes and proteins that affect the safety and efficacy of a drug in an individual patient. An understanding of these polymorphisms has the potential to enhance patient care by allowing physicians to customize the selection of medication to meet individual patient needs. Pharmacogenomics may also lead to improved compliance and shorter time to optimal disease management, thereby reducing morbidity and mortality. Significant cost savings could result from reductions in polypharmacy as well as from fewer physician encounters and hospitalizations for exacerbations of underlying illness and because of adverse drug reactions.
Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA. rkisabeth@mayo.edu
J M
JM
Rusnak
R M
RM
Kisabeth
D P
DP
Herbert
D M
DM
McNeil
D019090:Case Management / Q000458:organization & administration; D019295:Computational Biology; D005838:Genotype; D017048:Health Care Costs; D006801:Humans; D005791:Patient Care; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype; D011110:Polymorphism, Genetic